In a 54‑year‑old woman with persistently mildly elevated red‑cell indices that have plateaued, does this alter the diagnostic approach for polycythemia vera or other causes of erythrocytosis?

Yes, persistently mildly elevated but stable red-cell indices significantly alter the diagnostic approach and may warrant further investigation even without progression.

When hemoglobin/hematocrit levels remain mildly elevated but plateau, polycythemia vera (PV) should still be pursued if specific criteria are met, rather than simply observing. The diagnostic approach depends critically on whether PV-related features are present alongside the stable mild elevation.

Diagnostic Framework for Stable Mild Erythrocytosis

According to Mayo Clinic guidelines, the diagnostic possibility of PV should be entertained in three specific scenarios 1:

1. Hemoglobin/hematocrit above the 95th percentile for sex and race
2. Documented increase from individual baseline, regardless of where the value lies within the reference range
3. PV-related features accompanying borderline-high values, including:
   • Thrombocytosis
   • Leukocytosis
   • Microcytosis from iron deficiency
   • Splenomegaly
   • Aquagenic pruritus
   • Unusual thrombosis (including Budd-Chiari syndrome)
   • Erythromelalgia

If none of these three scenarios apply, a repeated blood test in 3 months suffices 1. However, if any are present—even with stable, mildly elevated indices—proceed with diagnostic workup.

Critical Pitfall: The Plasma Volume Issue

A major diagnostic trap exists with stable mild elevations: plasma volume expansion can mask true erythrocytosis. In PV, when red cell mass increases, plasma volume typically increases simultaneously 2. This means:

• Hematocrit <60% cannot reliably distinguish true erythrocytosis from pseudoerythrocytosis due to plasma volume contraction 2
• A "normal" or mildly elevated hematocrit may represent significant absolute erythrocytosis masked by expanded plasma volume
• This is particularly relevant in young women with isolated thrombocytosis and positive JAK2 V617F, where plasma volume expansion commonly obscures the diagnosis 2

Algorithmic Diagnostic Approach for Stable Mild Elevation

Step 1: Check for PV-Related Features

If any PV-related feature is present with borderline-high hematocrit, pursue full diagnostic workup regardless of stability 1.

Step 2: Measure Serum Erythropoietin

• Low EPO: PV probable (>90% specificity), proceed to bone marrow examination 1
• Normal EPO: PV still possible (sensitivity of low EPO for PV <70%), proceed to bone marrow examination 1
• High EPO: Evaluate for secondary polycythemia 1

Step 3: JAK2 Mutation Testing

The 2008 WHO criteria established JAK2 V617F as a major diagnostic criterion 3:

• Present in >90% of PV patients 3
• Positive JAK2 with any elevation warrants bone marrow examination to confirm diagnosis 3, 4, 5

Step 4: Bone Marrow Examination

Essential for definitive diagnosis, looking for 1, 5:

• Hypercellularity with trilineage growth (panmyelosis)
• Characteristic megakaryocyte changes
• Reticulin fibrosis assessment

Step 5: Consider Red Cell Mass Measurement

When diagnosis remains equivocal with stable mild elevation, direct red cell mass measurement is the gold standard 6, 2:

• Distinguishes absolute from relative (apparent) erythrocytosis
• Hemoglobin >185 g/L confirms absolute erythrocytosis in only 50% of males 6
• Red cell mass >25% above predicted normal confirms absolute erythrocytosis 3, 4

Why Stability Doesn't Exclude PV

PV can present with stable, mild elevations for several reasons:

1. Iron deficiency may lower a pathologically elevated red cell mass into the "mildly elevated" range 1
2. Concurrent conditions causing hypoxia (e.g., lung disease) may coexist with PV 1
3. Early disease phase may show modest elevations before progression 4
4. Plasma volume expansion masks the true red cell mass elevation 2

Practical Management Implications

For a 54-year-old woman with persistently mildly elevated but stable indices:

• Do not simply observe if cardiovascular risk factors or symptoms are present 7, 8
• Screen for JAK2 V617F mutation 3, 5, 9
• Measure serum EPO 1
• Assess for splenomegaly, thrombocytosis, leukocytosis 1
• Consider bone marrow biopsy if JAK2 positive or EPO low/normal with clinical features 1, 5
• If diagnosis confirmed, initiate phlebotomy to hematocrit <45% and low-dose aspirin regardless of "mild" elevation 7

Key Caveat

The 2016 WHO criteria lowered diagnostic hemoglobin thresholds to >16.5 g/dL (men) and >16.0 g/dL (women), recognizing that PV can present with more modest elevations 9, 7. Stability of mildly elevated values should not provide false reassurance—the thrombotic risk in untreated PV exists even with modest erythrocytosis, particularly when JAK2-mutated 7.